The company produces Hintermann Series products for the lower extremity, including H3 three-piece total ankle replacement prosthesis devices such as standard, sensitive and revision systems.

Other devices include Kalix II subtalar arthrodesis implant to treat flatfoot deformities, as well as instrumentation that will support the implantable devices.

Hintermann Series products have been approved in different countries, including Australia, Austria, Belgium, Canada, Costa Rica, Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy and South Korea.

The products are also available in Latvia, Lithuania, Luxembourg, Malaysia, Netherlands, New Zealand, Panama, Portugal, Russia, Sweden, Switzerland, Thailand, UAE, and the UK.

According to the company, distribution channels were secured to handle products in approved countries, with HealthLink Europe delivering the majority of logistics outside the US.

DTMT president and CEO David Reicher said: "Through hard work and sheer determination, everyone at DT MedTech can finally see the successful results of their efforts. We thank them all.”

 DTMT is engaged in the development of novel surgical solutions for lower extremity surgeons.

The company has offices in Baltimore of Maryland and Salt Lake City of Utah in the US. It also has offices in Dublin of Ireland, Saint-Louis of France and Liestal of Switzerland.

Image: DT MedTech’s H3 ankle. Photo: courtesy of PRNewsFoto / DT MedTech, LLC.